CHINA HEALTH GRP HD-10 - Asset Resilience Ratio
CHINA HEALTH GRP HD-10 (VNL1) has an Asset Resilience Ratio of 1.54% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read VNL1 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how CHINA HEALTH GRP HD-10's Asset Resilience Ratio has changed over time. See VNL1 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CHINA HEALTH GRP HD-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CHINA HEALTH GRP HD-10 (VNL1) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.70 Million | 1.54% |
| Total Liquid Assets | €1.70 Million | 1.54% |
Asset Resilience Insights
- Limited Liquidity: CHINA HEALTH GRP HD-10 maintains only 1.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CHINA HEALTH GRP HD-10 Industry Peers by Asset Resilience Ratio
Compare CHINA HEALTH GRP HD-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439 |
Diagnostics & Research | 7.27% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 37.17% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 2.14% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for CHINA HEALTH GRP HD-10 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for CHINA HEALTH GRP HD-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.68% | €1.70 Million ≈ $1.98 Million |
€100.96 Million ≈ $118.03 Million |
-0.97pp |
| 2023-12-31 | 2.65% | €3.16 Million ≈ $3.70 Million |
€119.35 Million ≈ $139.53 Million |
-1.83pp |
| 2022-12-31 | 4.48% | €8.01 Million ≈ $9.36 Million |
€178.62 Million ≈ $208.83 Million |
+1.57pp |
| 2021-12-31 | 2.91% | €5.66 Million ≈ $6.62 Million |
€194.32 Million ≈ $227.19 Million |
-- |
About CHINA HEALTH GRP HD-10
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research… Read more